Cadonilimab plus chemotherapy ± bevacizumab as 1L treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): a randomized, double-blind, placebo-controlled phase 3 study (Compassion-16)

被引：0
|
作者：
Wu, Xiaohua [1 ]
Sun, Yang [2 ]
Yang, Hongying [3 ]
Wang, Jing [4 ,5 ]
Lou, Hanmei [6 ]
Li, Dan [7 ]
Wang, Ke [8 ]
Zhang, Hui [9 ]
Wu, Tao [10 ]
Li, Yuzhi [11 ]
Wang, Chunyan [12 ]
Li, Guiling [13 ]
Wang, Yifeng [14 ]
Li, Dapeng [15 ]
Tang, Ying [16 ]
Pan, Mei [17 ]
Cai, Hongyi [18 ]
Liu, Ting [19 ]
Xia, Michelle [19 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fujian Med Univ, Clin Oncol Sch, Fujian Canc Hosp, Fuzhou, Peoples R China
[3] Yunnan Canc Hosp, Kunming, Peoples R China
[4] Cent South Univ, Hunan Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[5] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[6] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[7] Southwest Med Univ, Affiliated Hosp, Luzhou, Peoples R China
[8] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[9] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
[10] Changde First Peoples Hosp, Changde, Peoples R China
[11] Bengbu Med Univ, Affiliated Hosp 1, Bengbu, Peoples R China
[12] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[13] Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[14] Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China
[15] Shandong First Med Univ, Canc Hosp, Jinan, Peoples R China
[16] Chongqing Univ, Affiliated Canc Hosp, Chongqing, Peoples R China
[17] Jiangxi Maternal & Child Hlth Hosp, Nanchang, Peoples R China
[18] Gansu Prov Hosp, Lanzhou, Peoples R China
[19] Akeso Biopharm Inc, Zhongshan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB014/#167
引用
收藏
页码：A1 / A2
页数：2
相关论文
共 50 条
  • [21] Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
    Colombo, Nicoletta
    Biagioli, Elena
    Harano, Kenichi
    Galli, Francesca
    Hudson, Emma
    Antill, Yoland
    Choi, Chel Hun
    Rabaglio, Manuela
    Marme, Frederic
    Marth, Christian
    Parma, Gabriella
    Farinas-Madrid, Lorena
    Nishio, Shin
    Allan, Karen
    Lee, Yeh Chen
    Piovano, Elisa
    Pardo, Beatriz
    Nakagawa, Satoshi
    Mcqueen, John
    Zamagni, Claudio
    Manso, Luis
    Takehara, Kazuhiro
    Tasca, Giulia
    Ferrero, Annamaria
    Tognon, Germana
    Lissoni, Andrea Alberto
    Petrella, Mariacristina
    Laudani, Maria Elena
    Rulli, Eliana
    Uggeri, Sara
    Ginesta, M. Pilar Barretina
    LANCET ONCOLOGY, 2024, 25 (09): : 1135 - 1146
  • [22] Results from a phase 3, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in cancer patients not receiving chemotherapy or radiotherapy
    Glaspy, J. A.
    Smith, R. E.
    Aapro, M.
    Ludwig, H.
    Pinter, T.
    Smakal, M.
    Ciuleanu, T.
    Chen, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 136 - 136
  • [23] A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC)
    Carducci, M.
    Armstrong, A.
    Pili, R.
    Ng, S.
    Huddart, R.
    Agarwal, N.
    Khvorostenko, D.
    Lyulko, O.
    Brize, A.
    Vogelzang, N. J.
    Delva, R.
    Harza, M.
    Thanos, A.
    James, N.
    Werbrouck, P.
    Boegemann, M.
    Hutson, T.
    Milecki, P.
    Nederman, T.
    Sternberg, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S713 - S714
  • [24] TERRA: a randomized, double-blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer
    Kim, T. W.
    Shen, L.
    Xu, J. M.
    Sriuranpong, V.
    Pan, H.
    Xu, R.
    Han, S-W.
    Liu, T.
    Park, Y. S.
    Shir, C.
    Bai, Y.
    Bi, F.
    Ahn, J. B.
    Qin, S.
    Li, Q.
    Wu, C.
    Zhou, F.
    Ma, D.
    Srimuninnimit, V.
    Li, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results
    Coronel, Jaime
    Cetina, Lucely
    Pacheco, Irlanda
    Trejo-Becerril, Catalina
    Gonzalez-Fierro, Aurora
    de la Cruz-Hernandez, Erick
    Perez-Cardenas, Enrique
    Taja-Chayeb, Lucia
    Arias-Bofill, Daymi
    Candelaria, Myrna
    Vidal, Silvia
    Duenas-Gonzalez, Alfonso
    MEDICAL ONCOLOGY, 2011, 28 : S540 - S546
  • [26] A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results
    Jaime Coronel
    Lucely Cetina
    Irlanda Pacheco
    Catalina Trejo-Becerril
    Aurora González-Fierro
    Erick de la Cruz-Hernandez
    Enrique Perez-Cardenas
    Lucia Taja-Chayeb
    Daymi Arias-Bofill
    Myrna Candelaria
    Silvia Vidal
    Alfonso Dueñas-González
    Medical Oncology, 2011, 28 : 540 - 546
  • [27] KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer
    Schmid, Peter
    Baccan, Carlos
    Guo, Zifang
    Tryfonidis, Kostas
    Rugo, Hope S.
    CANCER RESEARCH, 2022, 82 (04)
  • [28] KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer
    Rugo, Hope S.
    Sohn, Joohyuk
    Jerez Gilarranz, Yolanda
    Gonzalez-Cortijo, Lucia
    Sonnenblick, Amir
    Sabanathan, Dhanusha
    Pablo Korbenfeld, Ernesto
    Egle, Daniel
    Poirier, Brigitte
    Zagouri, Flora
    Matikas, Alexios
    Aksoy, Sercan
    Demirci, Umut
    Ramos-Elias, Pier
    Im, Seock-Ah
    Cardoso, Fatima
    Jia, Liyi
    Baccan, Carlos
    Tryfonidis, Konstantinos
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study
    Mettu, N. B.
    Twohy, E.
    Ou, F-S.
    Halfdanarson, T. R.
    Lenz, H. J.
    Breakstone, R.
    Boland, P. M.
    Crysler, O.
    Wu, C.
    Grothey, A.
    Nixon, A. B.
    Bolch, E.
    Niedzwiecki, D.
    Fruth, B.
    Schweitzer, B.
    Elsing, A.
    Hurwitz, H.
    Fakih, M. G.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [30] AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)
    Kang, Y.
    Ohtsu, A.
    Van Cutsem, E.
    Rha, S. Y.
    Sawaki, A.
    Park, S.
    Lim, H.
    Wu, J.
    Langer, B.
    Shah, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
12345